arsenic trioxide has been researched along with Precursor Cell Lymphoblastic Leukemia-Lymphoma in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (75.00) | 29.6817 |
| 2010's | 1 (25.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, GQ; Duan, XF; Wang, XD; Wu, YL; Xu, HZ; Yan, H; Zhao, M; Zhuang, HY | 1 |
| Hirano, T; Hu, XM; Oka, K | 1 |
| Bennett, JM; Dewald, GW; Gallagher, RE; Jain, V; Lee, S; Litzow, MR; Mazza, JJ; Paietta, EM; Racevskis, J; Rousey, SR; Tallman, MS | 1 |
| Bonapace, L; Bornhauser, BC; Bourquin, JP; Cario, G; Lindholm, D; Martinez, R; Niggli, FK; Schäfer, BW; Schrappe, M | 1 |
1 trial(s) available for arsenic trioxide and Precursor Cell Lymphoblastic Leukemia-Lymphoma
| Article | Year |
|---|---|
A phase II trial of arsenic trioxide for relapsed and refractory acute lymphoblastic leukemia.
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Humans; Oxides; Patient Selection; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Recurrence; Treatment Outcome | 2006 |
3 other study(ies) available for arsenic trioxide and Precursor Cell Lymphoblastic Leukemia-Lymphoma
| Article | Year |
|---|---|
Synergistic mitosis-arresting effects of arsenic trioxide and paclitaxel on human malignant lymphocytes.
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; CDC2 Protein Kinase; Cells, Cultured; Drug Synergism; Humans; Jurkat Cells; Mitosis; Oxides; Paclitaxel; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Tubulin Modulators | 2010 |
Arsenic trioxide induces apoptosis equally in T lymphoblastoid leukemia MOLT-4 cells and P-gp-expressing daunorubicin-resistant MOLT-4 cells.
Topics: Apoptosis; Arsenic Trioxide; Arsenicals; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cell Division; Cell Survival; Daunorubicin; Drug Resistance, Neoplasm; Humans; Oxides; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Tumor Cells, Cultured | 2003 |
Low-dose arsenic trioxide sensitizes glucocorticoid-resistant acute lymphoblastic leukemia cells to dexamethasone via an Akt-dependent pathway.
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; bcl-Associated Death Protein; Blotting, Western; Caspases; Cell Line, Tumor; Cell Survival; Dexamethasone; Drug Resistance, Neoplasm; Drug Synergism; Glucocorticoids; Humans; Neoplasm, Residual; Oxides; Phosphorylation; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prednisone; Proto-Oncogene Proteins c-akt; Reactive Oxygen Species; Remission Induction; RNA, Small Interfering; Signal Transduction; Sirolimus; Transfection; X-Linked Inhibitor of Apoptosis Protein | 2007 |